Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Biochemical and structural analyses suggest that plasminogen activators coevolved with their cognate protein substrates and inhibitors.

Jendroszek A, Madsen JB, Chana-Muñoz A, Dupont DM, Christensen A, Panitz F, Füchtbauer EM, Lovell SC, Jensen JK.

J Biol Chem. 2019 Mar 8;294(10):3794-3805. doi: 10.1074/jbc.RA118.005419. Epub 2019 Jan 16.

PMID:
30651349
2.

Blocking the proteolytic activity of zymogen matriptase with antibody-based inhibitors.

Tamberg T, Hong Z, De Schepper D, Skovbjerg S, Dupont DM, Vitved L, Schar CR, Skjoedt K, Vogel LK, Jensen JK.

J Biol Chem. 2019 Jan 4;294(1):314-326. doi: 10.1074/jbc.RA118.004126. Epub 2018 Nov 8.

PMID:
30409910
3.

Small-Molecule Probes for Affinity-Guided Introduction of Biocompatible Handles on Metal-Binding Proteins.

Mortensen MR, Skovsgaard MB, Okholm AH, Scavenius C, Dupont DM, Rosen CB, Enghild JJ, Kjems J, Gothelf KV.

Bioconjug Chem. 2018 Sep 19;29(9):3016-3025. doi: 10.1021/acs.bioconjchem.8b00424. Epub 2018 Aug 23.

PMID:
30091905
4.

An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.

Kuhlmann M, Hamming JBR, Voldum A, Tsakiridou G, Larsen MT, Schmøkel JS, Sohn E, Bienk K, Schaffert D, Sørensen ES, Wengel J, Dupont DM, Howard KA.

Mol Ther Nucleic Acids. 2017 Dec 15;9:284-293. doi: 10.1016/j.omtn.2017.10.004. Epub 2017 Oct 7.

5.

A Conjugate of Two tPA-Binding RNA Aptamers Efficiently Inhibits Fibrinolysis.

Bjerregaard N, Dupont DM, Andreasen PA.

Nucleic Acid Ther. 2017 Apr;27(2):95-104. doi: 10.1089/nat.2016.0637. Epub 2017 Jan 4.

PMID:
28051346
6.

An RNA Aptamer Inhibits a Mutation-Induced Inactivating Misfolding of a Serpin.

Madsen JB, Andersen LM, Dupont DM, Trelle MB, Johansen JS, Jensen JK, Jørgensen TJ, Andreasen PA.

Cell Chem Biol. 2016 Jun 23;23(6):700-8. doi: 10.1016/j.chembiol.2016.04.013. Epub 2016 Jun 2.

7.

Expected and unexpected features of protein-binding RNA aptamers.

Bjerregaard N, Andreasen PA, Dupont DM.

Wiley Interdiscip Rev RNA. 2016 Nov;7(6):744-757. doi: 10.1002/wrna.1360. Epub 2016 May 12. Review.

PMID:
27173731
8.

Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules.

Dupont DM, Bjerregaard N, Verpaalen B, Andreasen PA, Jensen JK.

Bioconjug Chem. 2016 Apr 20;27(4):918-26. doi: 10.1021/acs.bioconjchem.6b00007. Epub 2016 Mar 11.

PMID:
26926041
9.

Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools.

Dupont DM, Larsen N, Jensen JK, Andreasen PA, Kjems J.

Nucleic Acids Res. 2015 Dec 2;43(21):e139. doi: 10.1093/nar/gkv700. Epub 2015 Jul 10.

10.

Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.

Bjerregaard N, Bøtkjær KA, Helsen N, Andreasen PA, Dupont DM.

Thromb Haemost. 2015 Jul;114(1):139-49. doi: 10.1160/TH14-08-0686. Epub 2015 Apr 9.

PMID:
25855589
11.

Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.

Dupont DM, Thuesen CK, Bøtkjær KA, Behrens MA, Dam K, Sørensen HP, Pedersen JS, Ploug M, Jensen JK, Andreasen PA.

PLoS One. 2015 Mar 20;10(3):e0119207. doi: 10.1371/journal.pone.0119207. eCollection 2015. Erratum in: PLoS One. 2015;10(4):e0126782.

12.

Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry.

Trelle MB, Dupont DM, Madsen JB, Andreasen PA, Jørgensen TJ.

ACS Chem Biol. 2014 Jan 17;9(1):174-82. doi: 10.1021/cb400619v. Epub 2013 Nov 14.

PMID:
24138169
13.

Interest of modelling in rheumatoid arthritis.

Beresniak A, Dupont DM, Becker JC, Merkesdal S.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S96-101. Epub 2012 Oct 18. Review.

PMID:
23078913
14.

Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.

Botkjaer KA, Deryugina EI, Dupont DM, Gårdsvoll H, Bekes EM, Thuesen CK, Chen Z, Ploug M, Quigley JP, Andreasen PA.

Mol Cancer Res. 2012 Dec;10(12):1532-43. doi: 10.1158/1541-7786.MCR-12-0349. Epub 2012 Oct 4. Erratum in: Mol Cancer Res. 2013 Aug;11(8):964. Chen, Zhou [corrected to Chen, Zhuo].

15.

Nucleic acid aptamers against proteases.

Dupont DM, Andersen LM, Botkjaer KA, Andreasen PA.

Curr Med Chem. 2011;18(27):4139-51. Review.

PMID:
21838691
16.

Tumor-targeted polydiacetylene micelles for in vivo imaging and drug delivery.

Mackiewicz N, Gravel E, Garofalakis A, Ogier J, John J, Dupont DM, Gombert K, Tavitian B, Doris E, Ducongé F.

Small. 2011 Oct 4;7(19):2786-92. doi: 10.1002/smll.201100212. Epub 2011 Aug 12.

PMID:
21837631
17.

Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.

Dupont DM, Madsen JB, Hartmann RK, Tavitian B, Ducongé F, Kjems J, Andreasen PA.

RNA. 2010 Dec;16(12):2360-9. doi: 10.1261/rna.2338210. Epub 2010 Oct 20.

18.

In vivo validation of free-space fluorescence tomography using nuclear imaging.

Garofalakis A, Dubois A, Kuhnast B, Dupont DM, Janssens I, Mackiewicz N, Dollé F, Tavitian B, Ducongé F.

Opt Lett. 2010 Sep 15;35(18):3024-6. doi: 10.1364/OL.35.003024.

PMID:
20847766
19.

RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.

Madsen JB, Dupont DM, Andersen TB, Nielsen AF, Sang L, Brix DM, Jensen JK, Broos T, Hendrickx ML, Christensen A, Kjems J, Andreasen PA.

Biochemistry. 2010 May 18;49(19):4103-15. doi: 10.1021/bi100066j.

PMID:
20387790
20.

Biochemical properties of plasminogen activator inhibitor-1.

Dupont DM, Madsen JB, Kristensen T, Bodker JS, Blouse GE, Wind T, Andreasen PA.

Front Biosci (Landmark Ed). 2009 Jan 1;14:1337-61. Review.

21.

Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements.

Blouse GE, Dupont DM, Schar CR, Jensen JK, Minor KH, Anagli JY, Gårdsvoll H, Ploug M, Peterson CB, Andreasen PA.

Biochemistry. 2009 Mar 3;48(8):1723-35. doi: 10.1021/bi8017015.

PMID:
19193026
22.

A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.

Mathiasen L, Dupont DM, Christensen A, Blouse GE, Jensen JK, Gils A, Declerck PJ, Wind T, Andreasen PA.

Mol Pharmacol. 2008 Sep;74(3):641-53. doi: 10.1124/mol.108.046417. Epub 2008 Jun 17.

PMID:
18559377
23.

Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C.

Dupont DM, Blouse GE, Hansen M, Mathiasen L, Kjelgaard S, Jensen JK, Christensen A, Gils A, Declerck PJ, Andreasen PA, Wind T.

J Biol Chem. 2006 Nov 24;281(47):36071-81. Epub 2006 Oct 3.

24.

Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.

Durand MK, Bødker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, Wind T, Andreasen PA.

Thromb Haemost. 2004 Mar;91(3):438-49. Review.

PMID:
14983218
25.

Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.

Jensen JK, Durand MK, Skeldal S, Dupont DM, Bødker JS, Wind T, Andreasen PA.

FEBS Lett. 2004 Jan 2;556(1-3):175-9.

26.

Mutational analysis of plasminogen activator inhibitor-1.

Wind T, Jensen JK, Dupont DM, Kulig P, Andreasen PA.

Eur J Biochem. 2003 Apr;270(8):1680-8.

Supplemental Content

Loading ...
Support Center